» Articles » PMID: 33545260

Long-term Follow-up of Patients with Infective Endocarditis in a Tertiary Referral Center

Overview
Journal Int J Cardiol
Publisher Elsevier
Date 2021 Feb 5
PMID 33545260
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Infective endocarditis (IE) remains a severe disease with high mortality. Most studies report on short-term outcome while real world long-term outcome data are scarce. This study reports reinfection rates and mortality data during long-term follow-up.

Methods: A total of 270 patients meeting the modified Duke criteria for definite IE admitted to a tertiary care center between July 2000 and June 2007 were analyzed retrospectively. Early reinfection was defined as a new IE episode within 6 months; late reinfection as a new IE episode beyond 6 months follow-up.

Results: Median follow-up was 8.5 years. Early reinfection occurred in 10 patients (3.7%), late reinfection in 18 patients (6.7%). Staphylococci (39.7%) were the most frequent causative microorganisms, followed by Streptococci (30.0%) and Enterococci (17.8%). Independent predictors of any reinfection were heart failure (HR 3.02, 95% CI 1.42-6.41), peripheral embolization (HR 4.00, 95% CI 1.58-10.17) and implanted pacemakers (HR 3.43, 95% CI 1.25-9.36). Survival rates were 71.1%, 55.2% and 43.3% at respectively 1-, 5- and 10-years follow-up. Independent predictors for mortality were age (HR 1.03, 95% CI 1.01-1.04), diabetes mellitus (HR 2.24, 95% CI 1.46-3.45), hemodialysis (HR 2.70, 95% CI 1.37-5.29), heart failure (HR 1.64, 95% CI 1.19-2.26), stroke (HR 1.73, 95% CI 1.18-2.52), antimicrobial treatment despite surgical indication (HR 5.53, 95% CI 3.59-8.49) and non-Streptococci causative microorganisms (HR 1.84, 95% CI 1.28-2.64).

Conclusions: Contemporary mortality rates of infective endocarditis remain high, irrespective of reinfection. Heart failure, peripheral embolization and presence of a pacemaker were predictors of reinfection.

Citing Articles

Clinical profile, microbiology and outcomes in infective endocarditis treated with aortic valve replacement: a multicenter case-control study.

Dingen H, Jordal S, Bratt S, Aukrust P, Busund R, Jakobsen O BMC Infect Dis. 2024; 24(1):913.

PMID: 39227795 PMC: 11370320. DOI: 10.1186/s12879-024-09782-3.


Infective Endocarditis in Belgium: Prospective Data in Adults from the ESC EORP European Endocarditis Registry.

Roosens B, Cosyns B, Lancellotti P, Laroche C, Selton-Suty C, Pasquet A J Clin Med. 2024; 13(5).

PMID: 38592201 PMC: 10932099. DOI: 10.3390/jcm13051371.


Performance of the SHARPEN Score and the Charlson Comorbidity Index for In-Hospital and Post-Discharge Mortality Prediction in Infective Endocarditis.

Alves S, Pivatto Junior F, Filippini F, Dannenhauer G, Seroiska G, Bischoff H Arq Bras Cardiol. 2024; 120(12):e20230441.

PMID: 38451614 PMC: 11021123. DOI: 10.36660/abc.20230441.


Combining C-reactive protein, procalcitonin, and serum albumin to predict long-term mortality in patients with infective endocarditis.

Karaca B, Esin F, Tiryaki M, Akkan G, Kiris T J Int Med Res. 2023; 51(10):3000605231208910.

PMID: 37891466 PMC: 10612466. DOI: 10.1177/03000605231208910.


Sex-related disparities in the incidence and outcomes of infective endocarditis according to type 2 diabetes mellitus status in Spain, 2016-2020.

Lopez-de-Andres A, Jimenez-Garcia R, Hernandez-Barrera V, de-Miguel-Diez J, de-Miguel-Yanes J, Martinez-Hernandez D Cardiovasc Diabetol. 2022; 21(1):198.

PMID: 36180922 PMC: 9524731. DOI: 10.1186/s12933-022-01633-2.